Purity and potency.

ACRO urges Congress to add clinical screening in biosimilars legislation The Association of Clinical Research Agencies has called on Congress to ensure that any biosimilars legislation it passes requires clinical testing to make sure patient safety, efficacy, purity and potency.D., Executive Director of ACRO prescription drugs .

Stovall, Senior Health Policy Advisor, National Coalition for Cancers Survivorship. ‘Incorporation of the new standard into the Commission’s accreditation process is an important milestone in implementation of a key suggestion of the Institute of Medicine’s 2005 consensus survey From Cancer Patient to Malignancy Survivor: Lost in Changeover,’ explained Ms. Stovall who served as Vice-Chair also, IOM Committee on Cancer Survivorship: Improving Care and Quality of Life. Promoting the best level of quality cancer treatment has been the foundation for Commission on Tumor standards always, and the brand new 2012 criteria contain new quality requirements. Of particular note is a fresh standard that will require CoC programs to reach specific performance levels on calculating quality for treating sufferers with breasts, colon, and rectal cancers.

You Might Also Like